search
Back to results

Clinical Implementation of Carrier Status Using Next Generation Sequencing (NextGen)

Primary Purpose

Genetic Disorders

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Whole Genome Sequencing
Carrier status testing
Sponsored by
Kaiser Permanente
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Genetic Disorders focused on measuring Whole Genome Sequencing, Carrier status, Genetics

Eligibility Criteria

21 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Seeking pre-conception carrier status testing or had carrier testing during pregnancy
  • Women with a male partner that can be contacted
  • Kaiser Permanente Northwest members
  • English speaking
  • Not currently pregnant

Exclusion Criteria:

  • Currently pregnant
  • No known or accessible male partner
  • Not an English speaker
  • Not a Kaiser Permanente member

Sites / Locations

  • Kaiser Permanente Northwest

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Usual care

Whole Genome Sequencing

Arm Description

Requested carrier status testing.

These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.

Outcomes

Primary Outcome Measures

Number of Patients That Receive Carrier Testing and Have Results to Return
The investigators will record the number of patients that have both single carrier status testing (usual care) and WGS testing and track how many patients have results to return.

Secondary Outcome Measures

Patient Satisfaction
Through surveys, interviews, and observations with patients, the investigators will assess their satisfaction with the testing and return of results process.

Full Information

First Posted
July 10, 2013
Last Updated
April 8, 2019
Sponsor
Kaiser Permanente
Collaborators
National Human Genome Research Institute (NHGRI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01902901
Brief Title
Clinical Implementation of Carrier Status Using Next Generation Sequencing
Acronym
NextGen
Official Title
Clinical Implementation of Carrier Status Using Next Generation Sequencing
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
January 2014 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
May 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kaiser Permanente
Collaborators
National Human Genome Research Institute (NHGRI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is conducting a randomized controlled trial (RCT) with up to 400 subjects (women & partners) seeking pre-conception carrier testing to assess the impact of the program using Whole Genome Sequencing (WGS). The investigators hypothesize that whole genome sequencing will increase the detection of carrier status for Mendelian recessive and x-linked conditions. The investigators hypothesize that parents will act on the knowledge of their carrier status by making different reproductive choices than parents who do not receive this information. The investigators hypothesize that the psychosocial risks are increased among parents who receive expanded carrier screening using Next Generation Sequencing (NGS) compared with usual care.
Detailed Description
Project 1-Clinical Intervention and Outcomes Aim 1: To conduct a randomized controlled trial (RCT) with up to 400 subjects (women & partners) seeking pre-conception carrier testing to assess the impact of the program using Whole Genome Sequencing (WGS). Aim 2: To develop processes for delivering information from WGS directly into the patient's electronic medical record, and establish innovative reporting strategies that are informative for clinicians and couples acting on this information. Aim 3: To measure for the integration of sequence information in clinical care for both carrier status and secondary findings including: Patient reported outcomes (PRO) on the impact on quality of life, satisfaction with care, timeliness of reporting, and use of the genomic information. Process outcomes such as timeliness, number of reportable findings, and time of interpretation. Project 2 -WGS technology, informatics, and Return of Results Committee (RORC) Aim 1: To generate whole genome sequence and interpret variants on samples randomized from the Kaiser Permanente Northwest (KPNW) preconception carrier screening cohort. To perform whole genome sequencing, assembly, and variant detection for each sample. To provide variant data on each sample with annotation and ranking of clinical significance. To validate data using an orthogonal platform for findings relevant to carrier status and actionable secondary findings. Aim 2: To develop and implement a return of results committee (RORC) that incorporates evidence to assess criteria for reporting carrier status for reproductive decision making and secondary findings. Project 3 - Ethical and Psychosocial Implications Aim 1: To evaluate, patient and clinical perspectives on informational needs, satisfaction, knowledge, and decision-making relating to the choice to obtain results of carrier status from WGS in four categories of genetic conditions. Aim 2: To evaluate, from patient and clinician perspectives, the immediate and downstream ethical, psychosocial, and behavioral consequences of expanded carrier screening using WGS. Aim 3: To evaluate the impact of expanded carrier test using WGS on subsequent health care utilization, and to compare the cost of delivery WGS to usual care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Genetic Disorders
Keywords
Whole Genome Sequencing, Carrier status, Genetics

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
384 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual care
Arm Type
Active Comparator
Arm Description
Requested carrier status testing.
Arm Title
Whole Genome Sequencing
Arm Type
Experimental
Arm Description
These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
Intervention Type
Genetic
Intervention Name(s)
Whole Genome Sequencing
Intervention Description
Participants will receive Whole Genome Sequencing
Intervention Type
Genetic
Intervention Name(s)
Carrier status testing
Intervention Description
Carrier status testing
Primary Outcome Measure Information:
Title
Number of Patients That Receive Carrier Testing and Have Results to Return
Description
The investigators will record the number of patients that have both single carrier status testing (usual care) and WGS testing and track how many patients have results to return.
Time Frame
Assessed annually for 4 years, data at the end of the study reported.
Secondary Outcome Measure Information:
Title
Patient Satisfaction
Description
Through surveys, interviews, and observations with patients, the investigators will assess their satisfaction with the testing and return of results process.
Time Frame
Assessed annually for 4 years, data at the end of Year 3 reported.
Other Pre-specified Outcome Measures:
Title
Healthcare Utilization
Description
The investigators will evaluate if expanded carrier testing using WGS causes an increase in subsequent health care utilization compared to usual care (typically just cystic fibrosis carrier testing).
Time Frame
The end of Year 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Seeking pre-conception carrier status testing or had carrier testing during pregnancy Women with a male partner that can be contacted Kaiser Permanente Northwest members English speaking Not currently pregnant Exclusion Criteria: Currently pregnant No known or accessible male partner Not an English speaker Not a Kaiser Permanente member
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katrina Goddard, PhD
Organizational Affiliation
Kaiser Permanente
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Benjamin Wilfond, MD
Organizational Affiliation
Seattle Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kaiser Permanente Northwest
City
Portland
State/Province
Oregon
ZIP/Postal Code
97227
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Genome sequencing data is shared with dbGaP, and variants are shared with Clinvar.
IPD Sharing Time Frame
Ongoing
IPD Sharing Access Criteria
Request to dbGaP

Learn more about this trial

Clinical Implementation of Carrier Status Using Next Generation Sequencing

We'll reach out to this number within 24 hrs